HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henkel

This article was originally published in The Rose Sheet

Executive Summary

Completion of the Dial purchase will result in an "immediate increase" in Henkel's operating profit, Dusseldorf, Germany firm announces during annual general meeting April 19. Henkel previously estimated the acquisition would add $1.48 bil. (€1=$1.23) to net revenue. "With Dial having generated sales of €1.2 bil. in fiscal 2003, the structure of Henkel group is bound to undergo significant changes both in terms of product portfolio and regional weighting," President and CEO Ulrich Lehner added. Dial shareholders approved the $2.9 bil. acquisition in March (1"The Rose Sheet" March 29, 2004, In Brief). Henkel said future Dial R&D will focus on products that address the "biologically active" portion of hair...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel